Dr. Mohindru is a skilled biotech executive with several years of biopharmaceutical industry leadership, coupled with experience on Wall Street. Dr. Mohindru currently serves as the chief executive officer at Novasenta, a biotech company focused on discovering novel targets for the treatment of cancer. Dr. Mohindru has served in numerous company leadership positions, including chief executive officer at CereXis, chief financial officer and chief strategy officer at Cara Therapeutics (Nasdaq: CARA) and chief strategy officer at Curis, Inc. (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent many years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a privately- held biotechnology company and was a healthcare industry consultant. Currently, she is a member of the board of directors of SAB Biotherapeutics, a clinical-stage biopharmaceutical company advancing a new class of immunotherapies. Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University, her master’s degree in biotechnology, and her B.S. in human biology with honors from the All India Institute of Medical Sciences, New Delhi, India.
Learn MoreMs. Gilbert brings 20 years of operational, transactional, and strategic leadership experience within the biopharmaceutical sector to CytomX, having served in roles overseeing the transformation of companies from development to the commercial stage. Currently, Ms. Gilbert serves as the Chief Legal Officer of CARGO Therapeutics, a position she has held since September 2023. Ms. Gilbert has also previously served as the Chief Legal Officer at NeoGenomics Laboratories, where she oversaw NeoGenomics’ global legal functions and affairs. Additionally, Ms. Gilbert has served in numerous corporate leadership positions including chief operating officer at Adagio Therapeutics and senior vice president, corporate development and chief administrative officer, at Ironwood Pharmaceuticals. Prior to Adagio and Ironwood, Ms. Gilbert served as vice president, deputy general counsel at Cubist Pharmaceuticals, Inc., where she managed the legal function during the company’s first commercial launch of an acute care antibiotic. Prior to her time with Cubist, Ms. Gilbert served as corporate counsel at Genzyme Corporation. Ms. Gilbert began her career at the law firm of Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert currently serves on the board of Arcutis Biotherapeutics and Vaxcyte, Inc. Ms. Gilbert received a J.D. from Northwestern University School of Law and a B.A. from Tufts University.
Learn MoreJames R. Meyers brings more than 30 years of worldwide commercial leadership experience within the biotechnology industry. Mr. Meyers served as Gilead’s executive vice president of worldwide commercial operations where he was responsible for all commercial activities including pricing and market access in North America, Europe, Middle East, Australia and Japan. Since his retirement in 2018, Mr. Meyers now serves as a senior advisor to the company. Over his 22-year career at Gilead, Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HCV and HIV. Prior to joining Gilead, Mr. Meyers held positions of increasing responsibility in sales, training, marketing and management with Zeneca Pharmaceuticals and Astra USA. Mr. Meyers currently serves on the Board of Arbutus Biopharma Corporation, a public biopharmaceutical company focused on commercializing a cure for patients suffering from chronic hepatitis B infection. Mr. Meyers holds a B.S. in economics from Boston College.
Learn MoreMatthew P. Young is a managing director of Longitude Capital. Prior to joining Longitude Capital in 2022, Mr. Young was the chief operating officer and chief financial officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina for $8 billion in 2021. Prior to joining GRAIL in October 2019, Mr. Young served as executive vice president and chief financial officer of Jazz Pharmaceuticals – a role he held since February 2015. He served as a senior vice president and the chief financial officer of Jazz beginning in 2014 after working as the senior vice president of corporate development of Jazz since joining the company in 2013. Prior to joining Jazz, Mr. Young worked in investment banking for approximately 20 years, most recently as a managing director in global healthcare of Barclays Capital Inc., an investment banking firm, where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., an investment banking firm, and from 2003 to 2007, as a managing director of Lehman Brothers Inc., an investment banking firm. In 2015, he joined the board of directors of PRA Health Sciences Inc., a contract research company. Mr. Young received a B.S. in economics and an M.B.A. from the Wharton School of the University of Pennsylvania.
Learn MoreCharles S. Fuchs, M.D., M.P.H., is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development, and conducts research assessing novel therapeutic approaches in oncology. Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.
Learn MoreDr. Sean McCarthy joined CytomX in December 2010 as our chief business officer and became a member of our board of directors and our president and chief executive officer in August 2011. On January 1, 2019, Dr. McCarthy became chairman of our board of directors. Dr. McCarthy has more than twenty-five years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Following completion of his post-doctoral training at the Schering Plough DNAX Research Institute, Dr. McCarthy held research leadership and program management roles at Millennium Pharmaceuticals where he managed biologics discovery programs. From Millennium, Dr. McCarthy joined SGX Pharmaceuticals, where he spearheaded a wide range of large pharma partnerships as vice president business development and helped drive a strategic reorientation of the company from a platform business model to product-focused oncology company, leading to a successful initial public offering in 2006. Immediately prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, where he was responsible for investments in therapeutic, medical device and molecular diagnostic companies. Dr. McCarthy is an author on multiple peer reviewed scientific publications, issued patents and filed patent applications. He received a B.Sc. in biochemistry and pharmacology from King’s College, University of London, an MBA from the Rady School of Management at the University of California San Diego and a D.Phil. in cancer biology from St. John’s College, University of Oxford. Dr. McCarthy currently serves as a member of the Board of Directors of OncoResponse, Inc. and is member of the Dean’s Advisory Council at the UCSD Rady School of Management.
Learn MoreDr. Ashworth is a world-renowned expert in cancer research and a global leader in cancer therapy development. He serves in multitude of roles, including as the president of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center; senior vice president for cancer services at UCSF Health; a professor of medicine within the division of hematology/oncology, department of medicine; and the E. Dixon Heise Distinguished Professor in Oncology. Previously, Dr. Ashworth was chief executive officer of the Institute of Cancer Research and director of the Breakthrough Breast Cancer Center in London, U.K. He is an elected member of the European Molecular Biology Organization, the Academy of Medical Sciences, and a Fellow of the Royal Society. Dr. Ashworth has received a number of scientific prizes and awards, including the European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation, the Meyenburg Foundation’s Cancer Research Award, the Basser Global Prize, the Genetics Society Medal, and the Susan G Komen Brinker award. Dr. Ashworth received his Ph.D. in biochemistry from University College London, U.K., and his B.Sc. in chemistry and biochemistry from Imperial College of Science and Technology, University of London, U.K.
Learn MoreDr. Su joined our Board of Directors in March 2024. Currently, Dr. Su serves as the Chief Executive Officer of Marengo Therapeutics and member of its Board of Directors, having held both positions since July 2021. Prior to joining Marengo, Dr. Su served as Senior Vice President and Global Head of the Oncology Business Franchise for Merck KGaA from March 2019 to July 2021 and concurrently as Merck’s US Head of its Oncology Business Unit between July 2020 to July 2021. Dr. Su served as Chief Medical Officer of EMD Serono, part of the larger Merck group, from October 2017 to May 2019. Dr. Su currently serves as a member of the Board of Directors at Karyopharm Therapeutics Inc., a position he has held since August 2023. Before his career in the life sciences industry, Dr. Su served on the faculty of Duke University Medical School between 2001 to 2006, where he led early oncology clinical studies focusing on mRNA-based and cell-based immunotherapy, and then, between 2006 to 2009, served as the director of the Cell and Gene Therapy program at the University of Florida. Dr. Su received his Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.
Learn More